IRIDEX Corporation — Q3 2015 Form 10-Q
Reporting period: 13-week quarter ended October 3, 2015; nine-month period also ended October 3, 2015. Comparatives are for periods ended September 27, 2014. IRIDEX develops, manufactures and sells ophthalmic laser systems, delivery devices, consumables, and service and support. All dollar amounts below are in millions unless stated otherwise.
Financial results and liquidity
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Revenue | $9.815 | $10.118 | $29.644 | $31.036 |
| Gross profit / margin | $4.841 / 49.3% | $5.149 / 50.9% | $14.468 / 48.8% | $15.504 / 50.0% |
| Operating income (loss) | $0.143 | $0.606 | $(0.201) | $1.603 |
| Net income | $0.442 | $0.490 | $0.036 | $1.274 |
| Diluted earnings per share | $0.04 | $0.05 | $0.00 | $0.12 |
- Q3 revenue fell 3.0%; nine-month revenue fell 4.5%. System sales declined while recurring revenue increased: Q3 recurring revenue rose 8.9% to $4.989 million; nine-month recurring revenue rose 5.5% to $14.986 million.
- For the nine months, domestic and international system revenue were $6.592 million and $8.066 million, respectively; recurring revenue was $14.986 million.
- Nine-month operating cash flow was a use of $0.354 million, versus $2.660 million provided in the prior-year period. Investing used $1.059 million and financing used $1.677 million. Cash decreased $3.090 million to $10.213 million.
- At October 3, cash was $10.213 million, working capital was $24.3 million, and total liabilities were $7.831 million. The company reported no fixed or variable-rate debt outstanding.
- Inventory increased to $11.184 million from $9.119 million at January 3, 2015. Total assets were $40.651 million and stockholders’ equity was $32.820 million.
Changes versus the comparable periods
- Management attributed weaker system sales to production and quality problems that began during Q2 2015, shipment reductions—particularly to international distributors—and capacity constraints from strengthened outgoing quality checks. The company said it believed the quality issues were resolved and resumed system shipments in Q3, but shipments remained below historic levels.
- International system revenue declined 17.5% in both the quarter and nine-month comparison. Management also cited adverse effects from foreign-exchange movements. U.S. revenue grew, accounting for 59.0% of Q3 sales versus 54.8% a year earlier.
- Gross margin declined 1.6 percentage points in Q3 and 1.2 points for the nine months. Management cited lower direct margins and overtime/manufacturing overhead in Q3; over nine months, manufacturing costs remained relatively constant as revenue declined.
- Nine-month R&D and sales and marketing expenses increased 11.2% and 11.7%, respectively, while general and administrative expense decreased 7.0%. Operating results shifted from prior-year nine-month profit to a loss.
Outlook, risks and unusual items
- No specific revenue, earnings, or margin guidance was provided. Management said available cash and expected operating cash flows should provide sufficient liquidity for the next 12 months.
- Management identified quality control, production capacity and product reliability as significant risks to shipments, costs, customer acceptance and results. Other key risks include international distributor dependence and currency-related competitiveness, competition, regulatory approvals and compliance, reimbursement uncertainty, and supplier concentration.
- The February 2015 launch of the Cyclo G6 glaucoma platform was described as a strategic expansion into capital equipment and recurring single-use procedural sales.
- Q3 other income included a favorable earn-out fair-value adjustment. The earn-out liability was $0.966 million at October 3, 2015, down from $1.423 million at year-end; the liability is based on projected royalties and discount-rate estimates.
- The company repurchased 120,356 shares for $1.543 million during the nine months and paid approximately $0.275 million to cancel a former executive’s vested options. Approximately $1.1 million remained authorized for repurchases at quarter-end.
- Contractual obligations totaled $9.884 million, including $8.514 million of purchase commitments and $1.370 million of operating leases. The filing reported no material off-balance-sheet arrangements. Ordinary-course legal matters were not expected by management to have a material adverse effect.
- The company recorded a $0.103 million income-tax benefit for the nine months and reported $0.9 million of unrecognized tax benefits. It maintained the prior-year release of most deferred-tax valuation allowance.
Important facts for investors to verify
- Whether the reported resolution of manufacturing quality issues translates into restored system shipments and improved production capacity.
- Whether recurring-revenue growth and the Cyclo G6 launch can offset continued weakness in system sales, particularly internationally.
- Whether margins recover as volume, product mix, manufacturing costs and quality processes change.
- Whether operating cash flow improves, given the inventory build and cash decline, and whether management’s 12-month liquidity assessment remains supportable.
- The assumptions underlying the earn-out liability, deferred-tax asset realizability and remaining share-repurchase authorization.